NASDAQ · Financial Statements
Gracell Biotechnologies Inc. (GRCL) Financial Statements
$10.25
NASDAQ: GRCL
Market Cap $197.97M
Overview Financials Dividend Gracell Biotechnologies Inc. most recently reported annual revenue of $0, net profit of $-608.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2021 2022 Revenue $0 $0 $0 $0 $0 Operating Profit $-63.0M $-147.0M $-214.0M $-464.0M $-625.0M Net Profit $-61.0M $-132.0M $-197.0M $-466.0M $-608.0M EPS $-15.35 $-33.35 $-15.05 $-35.40 $-44.85 Op Margin — — — -126659.3% —
Balance Sheet (USD)
Metric 2018 2019 2020 2021 2022 Total Assets $149.0M $412.0M $965.0M $2.1B $1.7B Total Liabilities $146.0M $157.0M $145.0M $233.0M $281.0M Cash $12.0M $312.0M $754.0M $1.8B $1.5B Borrowings $139.0M $139.0M $103.0M $155.0M $183.0M
Cash Flow (USD)
Metric 2018 2019 2020 2021 2022 Operating Cash Flow $-62.0M $-135.0M $-198.0M $-305.0M $-3.3B Investing Cash Flow $-125.0M $-15.0M $-173.0M $-98.0M $-663.0M Financing Cash Flow $139.0M $350.0M $756.0M $1.5B $228.0M Net Cash Flow $-37.0M $300.0M $442.0M $1.1B $-2.6B Free Cash Flow $-73.0M $-192.0M $-278.0M $-361.0M $-3.6B
Valuation & Return Ratios
Metric Value PEG Ratio -0.08 EV / EBITDA -0.12 FCF Yield -271.40% Quick Ratio 6.78 Interest Coverage -92.72 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock